CALA Stock Overview
Operates under a plan of liquidation that was approved in January 2023. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Calithera Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0006 |
| 52 Week High | US$0.12 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 100.00% |
| 3 Month Change | -91.43% |
| 1 Year Change | -98.08% |
| 3 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate
Oct 03Calithera rises 8% after HC Wainwright upgrades rating to buy
Aug 29Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?
Aug 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully
Dec 17We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully
Aug 27The Upcoming Calithera Cystic Fibrosis Data Could Be Significant
Aug 03Calithera Biosciences Investor Presentation - Slideshow
May 08Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?
May 02What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?
Mar 10Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jan 17Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount
Jan 04Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth
Dec 13Calithera Biosciences Poised For Long-Term Success
Nov 25Calithera Biosciences (CALA) Investor Presentation - Slideshow
Nov 06Shareholder Returns
| CALA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -45.5% | 1.7% | -0.9% |
| 1Y | -98.1% | -2.2% | 22.6% |
Return vs Industry: CALA underperformed the US Biotechs industry which returned -2.2% over the past year.
Return vs Market: CALA underperformed the US Market which returned 22.6% over the past year.
Price Volatility
| CALA volatility | |
|---|---|
| CALA Average Weekly Movement | 908.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CALA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CALA's weekly volatility has decreased from 1896% to 909% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.calithera.com |
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences, Inc. Fundamentals Summary
| CALA fundamental statistics | |
|---|---|
| Market cap | US$2.92k |
| Earnings (TTM) | -US$21.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CALA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$28.53m |
| Gross Profit | -US$28.53m |
| Other Expenses | -US$7.24m |
| Earnings | -US$21.29m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CALA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 20:04 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Calithera Biosciences, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohit Bansal | Citigroup Inc |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Biren Amin | Jefferies LLC |